

Research Ethics Committee Reference Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target date to recruit patients agreed	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
15/NW/0160	171155	ABC08: A phase Ib, multi-centre, open-label study of a first-in-class nucleotide analogue Acelarin (NUC-1031) in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers	Number Agreed	4	4	Date Agreed	11/12/2018	3	23/03/2018	3	Recruitment Finished	Rare Patient Group
14/LO/2182	143226	NCRN - 3137: STOP-HCC TheraSphere in Unresectable Hepatocellular Carcinoma (HCC) TS103	Number Agreed	4	4	Date Agreed	01/06/2019	1	29/08/2017	1	Recruitment Finished	Rare Patient Group
17/WS/0030	191416	EVEREST : CANC - 4627: Medi4736 Pancreatic	Number Agreed	3	3	Date Agreed	01/11/2018	3	08/02/2018	3	Recruitment Finished	Target achieved
17/SC/0028	218036	CHECKMATE 714: A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (CheckMate	Number Agreed	3	3	Date Agreed	26/02/2018	5	26/02/2018	5	Recruitment Finished	Target exceeded
17/LO/0017	213632	9785- CL-0123 Open-label Extension Study for Participants with Prostate Cancer	Number Agreed	3	3	Date Agreed	30/04/2018	4	30/04/2018	4	Recruitment Finished	Target exceeded
15/LO/1635	178097	ABACUS (preoperative MPDL3280A)	Number Agreed	4	4	Date Agreed	07/05/2018	1	07/05/2018	1	Recruitment Finished	Rare Patient Group
16/NE/0316	207651	Phase 1 Study CYP-001 for the Treatment of Acute Graft vs Host Disease	Number Agreed	2	2	Date Agreed	23/05/2018	3	23/05/2018	3	Recruitment Finished	Target exceeded
13/NW/0697	137274	PiSARRO - p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	Number Agreed	4	4	Date Agreed	15/09/2019	2	03/05/2018	2	Recruitment Finished	CCC PI long term sickness absence